Balyasny Asset Management LLC raised its stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 66.7% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 500,000 shares of the biotechnology company’s stock after acquiring an additional 200,000 shares during the quarter. Balyasny Asset Management LLC owned approximately 0.60% of Aurinia Pharmaceuticals worth $3,065,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its holdings in shares of Aurinia Pharmaceuticals by 1.1% in the second quarter. Bank of New York Mellon Corp now owns 81,950 shares of the biotechnology company’s stock worth $502,000 after acquiring an additional 931 shares during the last quarter. Nicholas Investment Partners LP raised its holdings in shares of Aurinia Pharmaceuticals by 1.0% in the second quarter. Nicholas Investment Partners LP now owns 254,084 shares of the biotechnology company’s stock worth $1,557,000 after acquiring an additional 2,484 shares during the last quarter. UBS Group AG raised its holdings in shares of Aurinia Pharmaceuticals by 13.6% in the first quarter. UBS Group AG now owns 112,314 shares of the biotechnology company’s stock worth $824,000 after acquiring an additional 13,405 shares during the last quarter. FMR LLC raised its holdings in shares of Aurinia Pharmaceuticals by 0.3% in the second quarter. FMR LLC now owns 5,867,800 shares of the biotechnology company’s stock worth $35,969,000 after acquiring an additional 19,200 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Aurinia Pharmaceuticals in the first quarter worth $155,000. 27.76% of the stock is owned by institutional investors.
Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) opened at 6.43 on Wednesday. The stock’s market cap is $536.81 million. Aurinia Pharmaceuticals Inc has a 12 month low of $2.02 and a 12 month high of $10.54. The stock has a 50 day moving average price of $6.33 and a 200-day moving average price of $6.55.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.10. The company had revenue of $0.33 million during the quarter, compared to analyst estimates of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 28.61% and a negative net margin of 16,648.93%. On average, analysts forecast that Aurinia Pharmaceuticals Inc will post ($1.01) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Balyasny Asset Management LLC Has $3.07 Million Stake in Aurinia Pharmaceuticals Inc (AUPH)” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.themarketsdaily.com/2017/10/11/balyasny-asset-management-llc-has-3-07-million-stake-in-aurinia-pharmaceuticals-inc-auph.html.
AUPH has been the subject of a number of analyst reports. Zacks Investment Research raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Vetr raised Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $7.35 price target for the company in a report on Tuesday, September 19th. Seaport Global Securities reissued a “buy” rating and issued a $10.00 price target on shares of Aurinia Pharmaceuticals in a report on Friday, October 6th. Cantor Fitzgerald set a $14.00 price target on Aurinia Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 11th. Finally, BidaskClub cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 28th. One investment analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Aurinia Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $9.82.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.